Cardiovascular Effects of Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversity of Western Sao Paulo-
Autor(es): dc.contributorUniversidade Federal de Minas Gerais (UFMG)-
Autor(es): dc.contributorUniversidade Estadual Paulista (UNESP)-
Autor(es): dc.contributorFederal University of Espirito Santo-
Autor(es): dc.contributorState University of Feira de Santana-
Autor(es): dc.contributorDante Pazzanese Institute of Cardiology-
Autor(es): dc.creatorSobral, Milene Vitória Sampaio-
Autor(es): dc.creatorRodrigues, Livia Kneipp-
Autor(es): dc.creatorBarbosa, Abner Mácola Pacheco-
Autor(es): dc.creatorda Rocha, Naila Camila-
Autor(es): dc.creatorMoulaz, Isac Ribeiro-
Autor(es): dc.creatordos Santos, João Pedro Pereira-
Autor(es): dc.creatorOliveira, Bruno Henrique Couto-
Autor(es): dc.creatorMoreira, João Lucas de Magalhães Leal-
Autor(es): dc.creatorPacagnelli, Francis Lopes-
Autor(es): dc.creatorGuida, Camila Mota-
Data de aceite: dc.date.accessioned2025-08-21T20:48:10Z-
Data de disponibilização: dc.date.available2025-08-21T20:48:10Z-
Data de envio: dc.date.issued2025-04-29-
Data de envio: dc.date.issued2024-12-31-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.1007/s40256-025-00721-4-
Fonte completa do material: dc.identifierhttps://hdl.handle.net/11449/309665-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/309665-
Descrição: dc.descriptionBackground: Semaglutide has emerged as an effective medication for treating type 2 diabetes mellitus (DM). However, the cardiovascular effects and safety of this agent in patients with heart failure with preserved ejection fraction (HFpEF) are unclear. Objective: This systematic review and meta-analysis aimed to assess the clinical and laboratory effects of semaglutide compared to placebo in patients with HFpEF. Methods: We systematically searched EMBASE, PubMed, and Cochrane databases for randomized controlled trials (RCTs) and non-randomized cohorts, from inception to July 2024, comparing semaglutide versus placebo in patients with HFpEF. Statistical analyses were performed using R Studio 4.3.2. Mean difference (MD) and odds ratio (OR) with 95% confidence intervals (CIs) were pooled across trials. Results: This meta-analysis included three studies, two RCTs and one non-randomized cohort, reporting data on 1463 patients. The follow-up time of the studies was 52 weeks. Compared to placebo, the use of semaglutide was associated with a significant increase in the 6-min walk distance (MD 16.20; 95% CI 10.19–22.21; p < 0.01; I2 = 0%). Additionally, reductions were observed in systolic blood pressure (MD −2.22; 95% CI −3.60 to −0.83; p < 0.01; I2 = 0%), C-reactive protein level (MD 0.59; 95% CI 0.49–0.70; p < 0.01; I2 = 51%), and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) levels (MD 0.81; 95% CI 0.74–0.89; p < 0.01; I2 = 0%). Conclusion: These findings suggest that the use of semaglutide is associated with clinical and laboratory benefits in patients with HFpEF.-
Descrição: dc.descriptionUniversity of Western Sao Paulo-
Descrição: dc.descriptionFederal University of Minas Gerais-
Descrição: dc.descriptionSão Paulo State University-
Descrição: dc.descriptionFederal University of Espirito Santo-
Descrição: dc.descriptionState University of Feira de Santana-
Descrição: dc.descriptionDante Pazzanese Institute of Cardiology, Av. Dante Pazzanese-
Descrição: dc.descriptionSão Paulo State University-
Idioma: dc.languageen-
Relação: dc.relationAmerican Journal of Cardiovascular Drugs-
???dc.source???: dc.sourceScopus-
Título: dc.titleCardiovascular Effects of Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis-
Tipo de arquivo: dc.typevídeo-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.